PTN
Palatin Technologies, Inc. AMEX$20.04
Mkt Cap $521.2M
52w Low $2.00
62.2% of range
52w High $31.00
50d MA $20.92
200d MA $14.70
P/E (TTM)
-0.6x
EV/EBITDA
-0.1x
P/B
—
Debt/Equity
-0.0x
ROE
-193.0%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
0.94
50d MA
$20.92
200d MA
$14.70
Avg Volume
1.8M
About
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | -2.35 | -2.86 | -21.5% | 17.59 | -6.5% | +10.0% | +19.4% | +27.7% | +27.8% | +30.8% | — |
| Nov 14, 2025 | AMC | — | 4.26 | — | 10.80 | +0.0% | +17.9% | +25.6% | +27.8% | +34.2% | +111.3% | — |
| Sep 23, 2025 | AMC | -9.50 | -4.14 | +56.4% | 10.06 | +1.9% | +2.9% | +1.9% | -0.1% | -37.3% | -21.3% | — |
| May 21, 2025 | AMC | -0.17 | -0.53 | -211.8% | 6.00 | -8.3% | +0.0% | -8.3% | -16.7% | -16.7% | -16.7% | — |
| Feb 13, 2025 | AMC | -0.42 | -0.12 | +71.4% | 53.00 | -1.9% | -5.7% | -2.8% | -4.7% | -3.8% | -5.7% | — |
| Oct 1, 2024 | AMC | -0.55 | -0.51 | +7.3% | 44.00 | +1.1% | -6.8% | -5.7% | +0.0% | +3.4% | -1.1% | — |
| Sep 30, 2024 | AMC | -0.56 | -0.49 | +12.5% | 44.50 | +3.4% | -1.1% | -7.9% | -6.7% | -1.1% | +2.2% | — |
| May 15, 2024 | AMC | -0.66 | -0.53 | +19.7% | 103.50 | +1.4% | -1.4% | -3.4% | -1.4% | +0.0% | -1.4% | — |
| Feb 14, 2024 | AMC | -0.43 | -0.56 | -30.2% | 207.00 | -2.7% | -23.9% | -27.1% | -21.7% | -28.0% | -22.9% | — |
| Nov 14, 2023 | AMC | -0.75 | -0.48 | +36.0% | 96.00 | +1.0% | +3.6% | +0.5% | +2.1% | +1.6% | +4.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.50 | $51.00 | +3.0% | +7.1% | +1.0% | +4.0% | +2.0% | +3.0% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.50 | $51.00 | +3.0% | +6.1% | -3.0% | +0.0% | +0.0% | +7.1% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.50 | $37.50 | +0.0% | +14.7% | +29.3% | +29.3% | +32.0% | +48.0% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $48.50 | +1.0% | +14.6% | +11.5% | +17.7% | +18.8% | +19.8% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.00 | $60.00 | +0.0% | -0.8% | -2.5% | -9.2% | -3.3% | +8.3% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.00 | $63.50 | +0.8% | -1.6% | -4.8% | -5.6% | -7.1% | -13.5% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.50 | $55.00 | +0.9% | +0.9% | +0.0% | +11.0% | +5.5% | +15.6% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $103.50 | $104.00 | +0.5% | -9.2% | -8.7% | -12.1% | -12.6% | -12.1% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $92.50 | $95.00 | +2.7% | +6.5% | +4.9% | -1.6% | -1.6% | +11.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $120.50 | $110.50 | -8.3% | -14.1% | -15.4% | -17.0% | -15.4% | -14.1% |
Data updated apr 26, 2026 9:10pm
· Source: massive.com